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Abstract 
Purpose: To synthesize and evaluate the anti-hyperlipidemic activity of a novel series of N-
(benzoylphenyl)-2-furamides (3a, 3b, 4a, 4b and 4c).  
Methods: Compounds (3a, 3b, 4a, 4b and 4c) were successfully synthesized by reacting activated 
furan-2-carbonyl-chloride derivatives with aminobenzophenones at 60 °C for 36 h.  Hyperlipidemia was 
induced in overnight fasted rats by intraperitoneal administration of Triton WR-1339 (300 mg/kg). to 
overnight fasted rats. The rats were divided into six groups: control, hyperlipidemic, hyperlipidemic plus 
compounds 3b, 4b, 4c, and hyperlipidemic plus bezafibrate-treated. Eighteen hours later, blood 
samples were collected and plasma lipid profile determined using enzymatic methods. 
Results: At a dose of 15 mg/kg body weight, the elevated plasma triglyceride (TG) levels, total 
cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels were significantly reduced by 
compounds 4b (p < 0.001) and 4c (p < 0.0001) 18 h later, compared to the hyperlipidemic group. 
Furthermore, compounds 4b and 4c significantly increased high density lipoprotein cholesterol (HDL-C) 
levels by 29 and 34 %, respectively. 
Conclusion: The findings indicate the high potency of N-(benzolphenyl)-2-furamides (4b and 4c) as 
lipid-lowering agents. Thus, these compounds 4b and 4c may used as lead compounds for the 
development of new derivatives and agents for targeting dyslipidemia and cardiovascular diseases.                            
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Cardiovascular diseases have become a major 
health problem in developing countries. 
Hyperlipidemia is defined as high levels of lipids 
(fat, cholesterol and triglycerides) circulating in 
the bloodstream [1,2]. Epidemiological studies 
demonstrate that hyperlipidemia is the most 
prevalent indicator of susceptibility to 
atherosclerosis and heart diseases [3-5]. Thus, 
decreasing plasma lipid levels play a major role 
in the treatment and prevention of coronary heart 
diseases [6]. For this reason, many studies have 
been conducted to evaluate the potential lipid-
lowering activity of synthetic and naturally 
compounds. 
 
Triton WR-1339, a non-ionic detergent 
(oxyethylated tertiary octylphenol formaldehyde 
polymer) has been widely used in in vivo studies 
to produce acute hyperlipidemia in animal 
models in order to study the lipid-lowering effect 
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of natural or chemical drugs [7]. Triton WR-1339 
has been found to prevent the catabolism of 
triglycerol-rich lipoprotein by lipoprotein lipase 
[8,9].  
 
There are many classes of lipid-lowering agents 
in existence. Fibrates and their derivatives 
including bezafibrate are class of drugs widely 
used to treat hypertriglyceridemia [10].  
Bezafibrate significantly reduces serum 
triglyceride and free fatty acid levels [11]. The 
major mechanism of fibrates is by the induction 
of lipoprotein lipase and efficient reduction of 
apolipoprotein C-III-containing particles, which 
are markers for increased risk of atherosclerosis 
[12-14]. 
 
In the last decade, many studies have shown 
that furan derivatives have promising potentials 
as lipid-lowering agents [15-17]. Therefore, the 
present study focuses on the synthesis and 
pharmacological evaluation of a novel series of 
N-(benzoylphenyl)-2-furamides as models for 




Materials and methods 
 
All chemicals, reagents and solvents were of 
analytical grade and used directly without further 
purification. Chemicals and solvents were 
purchased from the corresponding companies 
(Sigma-Aldrich; St. Louis, MO, USA and Acros; 
Belgium). 
 
Melting points (MP) were recorded using 
Gallenkamp melting point apparatus and were 
uncorrected. Infrared (IR) spectra were recorded 
using Shimadzu IR Affinity-1 spectrophotometer. 
All samples were prepared as potassium 
bromide (Acros, Belgium) discs. 1H and 13C NMR 
spectra were recorded using Bruker 300 MHz 
(Avance III, Switzerland Department of 
chemistry, the University of Jordan). Chemical 
Shifts are given in δ units using TMS as an 
internal reference. Chemical shifts are given in δ 
(ppm) using TMS as internal reference; 
deuterated solvents were used and stated with 
each compound. Thin Layer Chromatography 
(TLC) was performed on 20 x 20 cm  aluminum 
plates pre-coated with fluorescent silica gel 
GF254 (Fluka, Germany) and visualized by UV 
light (at 254 and/or 360 nm). 
 
Synthesis of the targeted compounds 
 
5-(3-Hydroxyphenyl) furan-2-carboxylic acid (2): 
methyl-5-(3-hydroxyphenyl) furan-2-carboxylate 
(1) (1 g, 4.58 mmol) was treated with 10 mL of 10 
% sodium hydroxide solution (6N) at 90 °C  for 
24 h. Then, the solution was neutralized with 10 
% hydrochloric acid (2N), under ice conditions. 
The crude solid was filtered to afford methyl-5-(3-
hydroxyphenyl) furan-2-carboxylic acid (2) as a 
white powder. 
 
5-(3-Hydroxyphenyl) furan-2-carbonyl chloride 
(3): 5-(3-hydroxyphenyl) furan-2-carboxylic acid 
(2) (0.75 g, 3.675 mmol) was treated with oxalyl 
chloride (0.63 mL, 7.2 mmol). Thereafter, the 
solution was refluxed for 48 h and then 
evaporated under reduce pressure. The crude 
product was then co-evaporated twice with (10 
mL) benzene to give 5-(3-hydroxyphenyl) furan-
2-carbonyl chloride (3) as pale yellow solid. 
 
N-(4-Benzoylphenyl)-5-(3-hydroxyphenyl)-2-
furamide (3a): 5-(3-hydroxyphenyl) furan-2-
carbonyl chloride (3) (0.5 g, 2.10 mmol) was 
dissolved in 10 mL dichloromethane (DCM). 
Then 100 mg of 4-(dimethylamino) pyridine 
(DMAP) was added. The mixture was stirred at 
room temperature for 15 min. Then 0.82 g, 4.20 
mmol of 4-aminobenzophenon and 10 mL N, N 
dimethylformamide (DMF) were added to the 
reaction mixture.  






























(3b) (4b) (4c)  
   Figure 1: Chemical structures of novel N-(benzoylphenyl)-2-furamides (3a, 3b, 4a, 4b and 4c) 
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The reaction mixture was heated at 60 °C for 36 
h. Solvents were evaporated and the residue 
was purified by column chromatography using 
chloroform (100 %) as eluent to afford the 
targeted compound (3a) as a fine yellow solid. 
 
N-(3-Benzoylphenyl)-5-(3-hydroxyphenyl)-2-
furamide (3b): 5-(3-hydroxyphenyl) furan-2-
carbonyl chloride (3) (0.5 g, 2.10 mmol) was 
dissolved in 10 mL of dichloromethane. Then, 
100 mg of 4-(dimethylamino) pyridine was 
added. The mixture was stirred at room 
temperature for 15 min. Then (0.829 g, 4.206 
mmol) of 3-aminobenzophenon and 10 mL of N, 
N dimethylformamide were added to the reaction 
mixture. The reaction mixture was heated at 60 
°C for 36 h. Solvents were evaporated and the 
residue was purified by column chromatography 
using chloroform (100 %) as eluent to afford the 
targeted compound (3b) as a fine yellow solid.  
 
N-(4-Benzoylphenyl)-5-methyl-2-furamide (4a): 
5-methylfuran-2-carbonyl chloride (4) (0.5 g, 3.45 
mmol) was dissolved in (10 ml) of 
dichloromethane. Then, 100 mg of 4-
(dimethylamino) pyridine was added. The mixture 
was stirred at room temperature for 15 min. 
Then, (1.36 g, 6.91 mmol) of 4-
aminobenzophenon was added to the reaction 
mixture. The reaction mixture was heated at 60 
°C for 24 h. DCM was evaporated and the 
residue was purified by column chromatography 
using chloroform/methanol (80:20) as eluent to 




5-methylfuran-2-carbonyl chloride (4) (1g, 6.91 
mmol) was dissolved in (10 mL) of 
dichloromethane. Then, 100 mg of 4-
(dimethylamino) pyridine was added. The mixture 
was stirred at room temperature for 15 min. Then 
(2.72 g, 13.83 mmol) of 3-aminobenzophenon 
was added to the reaction mixture. The reaction 
mixture was heated at 60 °C for 24 h. DCM was 
evaporated and the residue was purified by 
column chromatography using 
chloroform/methanol (80:20) as eluent to afford 
the targeted compound (4b) as a white powder.  
 
N-(2-Benzoylphenyl)-5-methyl-2-furamide (4c): 
5-methylfuran-2-carbonyl chloride (4) (0.8 g, 5.53 
mmol) was dissolved in (10 mL) of 
dichloromethane.  Then, 100 mg of 4-
(dimethylamino) pyridine was added. The mixture 
was stirred at room temperature for 15 min. Then 
(2.18 g, 11.06 mmol) of 2-aminobenzophenon 
was added to the reaction mixture. The reaction 
mixture was heated at 60 °C for 24 h. DCM was 
evaporated and the residue was purified by 
column chromatography using 
chloroform/methanol (80:20) as eluent to afford 
the targeted compound (4c) as a white powder.  
 
Animals and treatments 
 
Male Wistar rats weighing 180 g were obtained 
from the animal house of the Faculty of 
Pharmacy, Al-Zaytoonah University of Jordan. 
The animals were provided ad libitum access 
only to tap water throughout the experimental 
duration and maintained in a 12 h light-dark cycle 
under standard laboratory conditions (22 ± 2 °C).  
 
Principles of laboratory animal care as described 
in the European Community guidelines were 
followed [18]. All experiments were approved by 
the Animal Welfare Committee of the University 
(approval ref no. 6ZAWC/2016). 
 
Triton model of hyperlipidemia 
 
Acute hyperlipidemia was developed in animals 
by intraperitoneal administration of Triton WR-
1339 (Tyloxapol, Sigma-Aldrich) to the rats at a 
dose of (300 mg/kg body weight) [19]. 
 
Determination of anti-hyperlipidemic activity 
 
After injection of Triton, the overnight fasted rats 
were randomly divided into six groups of eight 
animals each. Normal control group (NCG) 
received an intraperitoneal administration of 
normal saline; hyperlipidemic control group 
(HCG) received an intraperitoneal injection of 
Triton WR-1339 dissolved in distilled water. In 
the third, fourth and fifth groups, hyperlipidemic 
rats were given intragastrically (15 mg/kg body 
weight) of compounds 3b, 4b and 4c 
respectively.  
 
In the last group the hyperlipidemic rats were 
given intragastrically (100 mg/kg body weight) of 
bezafibrate (BF) [20,21]. At 18 h following triton 
administration animals were anaesthetized and 
blood samples were collected from the renal 
artery. The blood samples were immediately 
centrifuged (3000 rpm for 10 min) and the serum 
was used for lipid profile analysis by an 
enzymatic method with an automated analyzer 




All anti-hyperlipidemic activity data are presented 
as mean ± SEM (n = 8). The data were analyzed 
using Student’s t-test, and p < 0.05 was 
Hikmat et al 
Trop J Pharm Res, January 2017; 16(1): 196  
 
considered statistically significant (SPSS version 






According to the proposed aims, a series of N-
(benzoylphenyl)-5-(3-hydroxyl phenyl)-2-
furamide (3a and 3b) were synthesized starting 
from methyl-5-(3-hydroxyphenyl)furan-2-
carboxylate (1) as shown in Scheme 1. Two 
different aminobenzophenone  substitutions were 
used, 4-aminobenzophenone for  compound N-
(4-benzoylphenyl)-5-(3-hydroxyphenyl)-2-




At the same time, a series of N-(benzoylphenyl)-
5-methyl-2-furamide (4a, 4b and 4c) were 
synthesized starting from 5-methylfuran-2-
carbonylchloride (4) as shown in (Scheme 2). 
Three  different aminobenzophenone 
substitutions were used, 4-aminobenzophenone 
for  compound N-(4-benzoylphenyl)-5-methyl-2-
furamide (4a), 3-aminobenzophenone for N-(3-







Yield 34 %; m.p.: 198-200 °C; Rf: 0.33 
(CHCl3)/MeOH, 98:2); IR (KBr) cm-1: 3263 (N-H), 
3055 (O-H), 1689 (CO, ketone), 1651 (CO, 
amide), 1597, 1527, 1411, 1311, 1280, 1180, 
925, 848, 786, 702, 594, 509, 424, 385 cm-1. 1H-
NMR (500 Hz, d6-DMSO) δ (ppm): 10.52 (br, s, 
1H, CONH), 8.38 (s, 1H, OH), 7.96 (s, 1H, Ar-H), 
7.71 (d, J = 1.35 Hz, 1H, furan-H), 7.66 (m, 6H, 
Ar-H), 7.55 (m,3H, Ar-H), 7.38 (d, J = 8.45 Hz, 
1H, furan-H), 7.25 (m, 1H, Ar-H), 6.6 (m, 2H, Ar-
H); 13C-NMR (d6-DMSO): δ = 195.3 (1C), 160.7 
(1C), 142.7 (1C), 137.9 (2C), 132.8 (2C), 132.3 
(1C), 132.2 (1C), 132.7 (2C), 129.8 (2C), 128.9 
(4C), 128.4 (1C),  127.6(1C), 127.0 (1C), 119.0 





Yield: 32 %; m.p.: 200-202 °C; Rf: 0.30 
(CHCl3/MeOH, 98:2); IR (KBr) cm-1: 3549 (N-H), 
3278 (O-H), 1680 (CO, ketone), 1658 (CO, 
amide), 1589, 1543, 1481, 1435, 1404, 1311, 
1280, 1165, 1126, 979, 902, 864, 786, 717, 648, 
594. 1H-NMR (300 Hz, CDCl3) δ(ppm): 8.85 (br, 
s , 1H, CONH), 8.74 (s, 1H, OH), 8,48 (s, 1H, Ar-
H), 8.34 (d, J = 3.0 Hz, 1H, furan-H), 7.96 (d, J = 
9.0 Hz, 1H, furan-H), 7.87 (s,1H, Ar-H), 7.76 (m, 
3H, Ar-H), 7.67 (m, 2H, Ar-H), 7.51 (m, 6H, Ar-
H); 13C-NMR (CDCl3) δ (ppm):  196.6 (1C), 
162.6 (1C), 159.7 (1C), 139.1 (1C), 138.3 (1C), 
137.5 (1C), 137.4 (1C),  137.1 (1C), 137.0 (1C), 
133.0 (1C), 132.8 (1C),  130.1 (2C), 129.7 (1C), 
129.1 (1C), 128.5 (1C), 128.4(2C), 126.8 (1C), 
126.4 (1C), 124.0 (1C), 122.4 (1C), 121.1 (1C), 
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Scheme 1: Synthesis of N-(benzoylphenyl)-5-(3-hydroxylphenyl)-2-furamide (3a, 3b). Reagents and conditions: 
(i): NaOH 10 % solution (6N)/reflux, 24 h; (ii): HCl (0 °C); (iii):C2O2Cl2, DCM/reflux (50 °C), 48 h; (iv): DMAP, 




Yield: 45 %; m.p.: 106-108 °C; Rf: 0.5 
(CHCl3/MeOH, 98:2); IR (KBr) cm-1: 3533 (N-H), 
3008 (CH3), 1666.52 (CO, ketone), 1666.50 (CO, 
amide), 1589, 1519, 1404, 1319, 1280, 1249, 
1211, 1134, 1018, 925, 848, 794, 748, 702, 624, 
509. 1H-NMR (500 Hz, CDCl3) δ(ppm):8.20 (br, 
s, 1H, CONH), 7.88 (d, J = 8.65 Hz, 2H, Ar-H), 
7.81 (m, 4H, Ar-H), 7.60 (t, J = 7.4 Hz, 1H, Ar-H), 
7.54 (t, J = 8 Hz, 2H, Ar-H), 7.20 (d, J = 3.35 
Hz,1H, furan-H), 6.21 (d, J = 2.65 Hz,1H, furan-
H), 2.43 ppm (s, 3H, CH3); 13C-NMR(CDCl3) 
δ(ppm): 195.6 (1C), 156.2 (1C), 155.4 (1C), 
145.8(1C), 141.6 (1C), 137.9 (1C), 133.0 (1C),  
132.2 (1C), 131.6 (2C), 129.8 (2C), 128.3 (2C),  




Yield: 38 %: m.p.: 105-106 °C; Rf: 0.55 (CHCl3 
/MeOH, 98:2); IR (KBr) cm-1: 3564 (N-H), 3062 
(CH3), 1674.21 (CO, ketone), 1674.20(CO, 
amide), 1597, 1519, 1481, 1427, 1357, 1319, 
1288, 1211, 1080, 1018, 964, 902, 871, 786, 
725, 586, 509. 1H-NMR (500 Hz, CDCl3) δ(ppm): 
8.17 (br, s, 1H, CONH), 8.12 (d, J = 1.0 Hz,1H, 
Ar-H), 7.93 (s, 1H, Ar-H), 7.84 (d, J = 1.3 Hz, 2H, 
Ar-H), 7.62 (t, J = 7.4Hz, 1H, Ar-H), 7.57 (d, J = 
7.7 Hz,1H, Ar-H), 7.51 (t, J = 7 Hz, 3H, Ar-H), 
7.17 (d, J = 3.35 Hz,1H, furan-H), 6.19 (d, J = 2.6 
Hz,1H, furan-H), 2.42 ppm (s, 3H, CH3); 13C-
NMR (CDCl3) δ(ppm): 196.2 (1C), 156.3 (1C), 
155.2 (1C), 145.8(1C), 138.3 (1C), 137.7 (1C), 
137.3 (1C),  132.6 (1C), 130.1 (2C), 129.1 (1C), 
128.3 (2C),  125.9(1C), 123.8 (1C), 121.0 (1C), 




Yield: 35 %: m.p.: 102-103 °C;  Rf; 0.7 (CHCl3 
/MeOH, 98:2); IR (KBr) cm-1: 3317 (N-H), 3124 
(CH3), 1674.21 (CO, ketone), 1620.21(CO, 
amide), 1597, 1519, 1489, 1435, 1357, 1311, 
1288, 1211, 1134, 1103, 1018, 925, 871, 802, 
748, 694, 632, 516, 447, 385. 1H-NMR (400 Hz, 
CDCl3) δ(ppm):δ = 11.72 (br, s, 1H,CONH), 8.79 
(d, J = 8.0 Hz,1H, furan-H), 7.72 (d, J = 8.0 Hz, 
2H, Ar-H), 7.60 (t, J = 12.0 Hz,3H,Ar-H), 7.26 (s, 
2H, Ar-H), 7.18 (d, J = 4.0 Hz,1H, Ar-H), 7.10 (t, 
J = 8.0 Hz, 1H, Ar-H), 6.15 (d, J = 4.0 Hz 1H, 
furan-H), 2.45 ppm (s, 3H, CH3);13C-NMR 
(CDCl3) δ(ppm): δ = 199.6 (1C), 156.9 (1C), 
155.7 (1C), 146.27 (1C), 140.4 (1C), 138.8 (1C), 
134.2 (1C), 133.7 (1C), 132.2 (2C), 129.7 (1C), 
128.2 (2C),  123.2(1C), 121.9 (1C), 121.4 (1C), 




The plasma total cholesterol (TC), triglyceride 
(TG), high-density lipoprotein-cholesterol (HDL-
C), and low-density lipoprotein-cholesterol (LDL-
C) levels in hyperlipidemic group (HCG) treated 
for 18 h are shown in (Figure 2). Triton WR-1339 
caused a significant increase in plasma TC, LDL-
C (p < 0.001), and TG (p < 0.0001) levels, and a 
significant decrease in HDL-C level (p < 0.001) in 
hyperlipidemic control group (HCG) after 18 h of 
Triton WR-1339 administration in comparison 
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Scheme 2: Synthesis of N-(benzoylphenyl)-5-methyl-2-furamides (4a, 4b and 4c). Reagents and condition: (i): 




Figure 2: Effect of Triton WR-1339 on plasma lipid profile after 18 h. Values are means ± SEM from eight 
animals in each group. NCG, control group; HCG, hyperlipidemic control group; TG, triglyceride; TC, total 
cholesterol; HDL-C, high density lipoprotein-cholesterol; LDL-C, low-density lipoprotein cholesterol. HCG is 
compared to NCG.*p < 0.001, .**p < 0.0001 
 
The increase of plasma total cholesterol 
concentration in the HCG was 147 % after 18 h 
as compared to the NCG. Triglyceride level in the 
HCG was also elevated by 887 % after 18 h. At 
the same time, LDL-C level in HCG was also 
elevated by 49 % after 18 h as compared to the 
NCG. HDL level in HCG was decreased by 14 % 
after 18 h as compared to NCG.  
 
Effect of compounds 3b, 4b, 4c and BF on 
plasma lipid profile in rats 
 
The effect of compounds 3b, 4b, 4c and BF on   
plasma lipid profile on treated rats after 18 h are 
shown in Table 1.  Interestingly, the elevated 
plasma TG levels produced by the acute injection 
of Triton WR-1339 were significantly (p < 0.0001) 
decreased by 71 and 67.5 % in compounds 4c 
and BF respectively and  by 56 % in 4b (p < 
0.001) after 18 h, in comparison to Triton treated 
hyperlipidemic control (HCG). Furthermore, total 
cholesterol levels were significantly (p < 0.01) 
reduced in 4b by 49 % and in 4c (p < 0.001) by 
50 % after 18 h compared to hyperlipidemic 
control group (HCG).  
 
After 18 h of treatment, LDL-cholesterol levels 
were lowered by (49 %, p < 0.0001) in 4c and 
(43.6 % p < 0.001) in compound 4b (Table 1). 
The HDL-C levels were significantly (p < 0.001) 
increased in compounds 4c and BF by 34 and 
36.5 % respectively and in 4b by 29 % (p < 0.01) 
after 18 h compared to HCG treated rats. No 
significant differences in TC, TG, HDL-C and 
LDL-C levels were observed by compound 3b in 





The results of the present study revealed the 
potential anti-hyperlipidemic activity of novel 
series of N-(benzoylphenyl)-2-furamides using 
Triton WR-1339-induced hyperlipidemic rats as a 
model for screening the lipid lowering potential 
[22]. 
 
Table 1:  Effect of compounds 3b, 4b, 4c and BF on plasma lipid levels in Triton WR 1339 induced 
hyperlipidemic rats after 18 h 
 
Compound       TG [mg/dl]  TC [mg/dl]  HDL [mg/dl] LDL [mg/dl] 
HCG  1264 ± 22.0 240 ± 9.0 41 ± 2.3  55 ± 1.3 
3b 1224 ± 21.0 242 ± 5.0 42 ± 2.7 52 ± 3.5 
4b 553 ±12.0 b 122 ± 2.0 a 53 ± 2.75 a 31 ±1.0 b 
4c 371 ± 5.0 c 119 ± 4.0 b 55 ± 3.2 b 28 ± 2.1c 
BF 411 ± 3.0 c  235 ± 2.0  56 ± 5.0 a  52 ± 1.6  
Values are means ± SEM from eight animals in each group. NCG: normal control group; HCG: hyperlipidemic 
control group; 3b: hyperlipidemic plus 3b; 4b: hyperlipidemic plus 4b; 4c: hyperlipidemic plus 4c; BF: 
hyperlipidemic plus Bezafibrate. TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein 
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cholesterol; LDL-C: low density lipoprotein cholesterol. 3b, 4b, 4c and BF are compared with HCG ᵃ p < 0.01, ᵇ p 
< 0.001, ᶜ p ˂ 0.0001 
 
Our results showed that the hyperlipidemia 
induced by Triton WR-1339 was significantly 
reduced by compounds 4b, 4c, and bezafibrate 
in comparison with the hyperlipidemic control 
group after 18 h. It was not surprising that the 
reduction in triglycerides levels of compounds 4b 
and 4c were significantly greater than the 
reduction in cholesterol levels; this could be 
explained by the significant elevation in plasma 
lipid profile following Triton WR-1339 
administration which results mostly from the 
increase in VLDL (in which the triglycerides 
portion is several times greater than that of 
cholesterol) [23]. This result suggests that the 
compounds are able to restore, at least partially, 
the catabolism of lipoproteins. 
 
In addition, 4b and 4c significantly increased the 
HDL-C levels after 18 h of Triton WR-1339 
administration. Elevated HDL-C is reported to 
have a preventive action against atherogenesis 
[24]. 
 
The findings of this research work are in 
agreement with our previous data which 
indicated that the presence of an aromatic 
heterocyclic moiety connected to huge lipophilic 
aromatic rings through a carboxamide linkage is 
necessary for interaction with proper target(s) for 
hypolipidemic activity [25,26]. Also, the chemical 
nature and the electronic effect of the 
substituents bearing on the heterocycle ring play 
an important role in the determination of activity. 
 
In the present study, the aromatic heterocycle is 
represented by furan ring and the aromatic 
lipophilic rings are benzophenones as shown in 
compounds 3b, 4b and 4c. Compounds 4b and 
4c demonstrated much more activity than 3b. 
This result may be explained by the chemical 
nature of the substituent on position 5 of the 
furan ring. In compounds 4b and 4c, the 
substituent is methyl group, a small lipophilic 
group while compound 3b harbors a phenolic 
group that offers H-bond donor and acceptor 
motif. The size of the substituent on position 5 is 
a determinant for the activity and this result may 
indicate that the adjacent area in the target(s) 
which receives the furan ring is a small lipophilic 
site. Therefore, the presence of methyl group 
provides good hydrophobic interaction in the 
binding cleft.  Interestingly, 4c exhibited better 
activity than 4b and this may be attributed to the 
possibility of intramolecular H-bond interaction 
which in turn affects drug/receptor interaction 
and thus, might infer that the binding site is 
lipophilic.  
 
At the same time, if compounds 4b with 4c are 
compared, 4c is more active than 4b and this 
may be due to the possibility of intramolecular 
hydrogen bond formation which means that the 
amide hydrogen and the oxygen atom of the keto 
group are not involved in hydrogen bond 
formation with the target(s); this may suggest 
that the area in the active site of the target(s) 





Compounds 4b and 4c improve lipid profile in 
Triton-induced hyperlipidemic rats. These 
findings are in agreement with previous reports, 
and thus confirm that the presence of lipophilic 
moiety, carboxamide linkage and a heterocyclic 
ring (capable of hydrogen bond formation, furan 
ring) are three important requirements for the 
hypolipidemic activity of these novel compounds. 
Thus, there is a need for further investigations to 
elucidate the exact mechanism of action of these 
compounds which can serve as lead compounds 
in the search for therapeutic agents for targeting 
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